Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOSINDYGO: Light Dose Escalation in Intraoperative PDT for Glioblastoma
NCT04391062Phase 2Completed
- Sponsor
- CHU de Lille
- Start
- Sep 2021
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of 5-aminolevulinic acid in glioblastoma (GBM), sponsored by CHU de Lille. Started Sep 2021; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04391062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04391062.